Gameto
Gameto is a clinical-stage biotechnology company engineering iPSC-derived ovarian support cells for women's reproductive health. Its lead program, Fertilo, is an OSC-IVM cell therapy for IVF and egg freezing currently in US Phase 3 trials and commercially cleared in approximately 12 countries.
- Company typePrivate
- Founded2021
- HeadquartersNew York, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Gameto does
Gameto is a clinical-stage biotechnology company developing therapeutics for the female reproductive system using engineered human induced pluripotent stem cells (hiPSCs). The company's proprietary cell engineering platform differentiates hiPSCs via transcription factor overexpression into FOXL2+ granulosa-like ovarian support cells (OSCs) and DDX4+ oogonia-like cells, which are used to mature oocytes ex vivo in a process termed OSC-IVM. Gameto operates three named programs on this platform: Fertilo, the lead program applying OSC-IVM to IVF and egg freezing; Ameno, a cell therapy for menopause symptoms (including a steroidogenic hormone-responsive bioengineered ovarian implant) supported by a $10 million ARPA-H award; and Deovo, a drug testing and development platform for ovarian disease built on the company's ovary-in-a-dish platform underpinned by exclusively licensed Harvard meiosis IP.
Fertilo, Gameto's commercial focus, reduces the conventional two-week IVF hormone injection protocol to approximately three days of minimal stimulation, achieves roughly 80% less hormone medication, and has reported MII oocyte maturation rates of approximately 71% versus approximately 43% for conventional IVM control. The therapy is cleared for commercial use in approximately 12 countries outside the United States and is investigational in the US, where a Phase 3 trial is underway at 15 clinics following FDA IND clearance in January 2025. Eleven live births via Fertilo have been reported globally, including the first live birth from an hiPSC-derived cell therapy on December 9, 2024.
Gameto generates revenue per treatment cycle outside the US through partner fertility clinics, while in the US it offers no-cost Phase 3 clinical trial enrollment via Accel Recruitment. The company is venture-backed, having raised $127 million cumulatively across Series A, B, and C rounds led by Future Ventures, RA Capital / Two Sigma Ventures, and Overwater Ventures, respectively. Its Tier-1 investor base includes Insight Partners, Lux Capital, and notable individuals such as Bob Nelsen (Arch Ventures) and Anne Wojcicki (23andMe). Gameto is incorporated in Delaware, headquartered in Austin, TX, with offices in New York (Alexandria Center for Life Sciences), Houston, Bee Cave (Texas), and a Europe regional presence in Spain.
Gameto firmographics
Firmographics- Name
- Gameto
- Legal name
- Gameto, Inc.
- Website
- https://gametogen.com
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Gameto is a clinical-stage biotechnology company engineering iPSC-derived ovarian support cells for women's reproductive health. Its lead program, Fertilo, is an OSC-IVM cell therapy for IVF and egg freezing currently in US Phase 3 trials and commercially cleared in approximately 12 countries.
- Ownership category
- akta.pro rank
Gameto industry classification
Industry- Product category
- Cell Therapy
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Reproductive Endocrinology & Infertility (IVF/Fertility) (HLAKAJAC)
- akta.pro secondary industries
- Fertility & Reproductive Endocrinology Telehealth (IVF/IUI, infertility evaluation) (HLALAHAA), Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ)
Keywords
Where Gameto is headquartered
LocationHeadquarters
- HQ city
- New York
- HQ country
- United States
- HQ region
- North America
Offices5 records
Markets served
Gameto business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Pre-commercial / Investigational therapy revenues: Fertilo is an investigational biologic in the U.S. Phase 3 trial with no FDA approval and no marketed revenue in the U.S. Outside the U.S. the therapy is offered commercially through partner clinics in approximately 12 countries, generating procedure-based / unit-based revenue per treatment cycle. Infertility impacts 1 in 6 people globally, defining the addressable market.
- Non-dilutive grant funding (ARPA-H): $10 million award through ARPA-H's Sprint for Women's Health Initiative to accelerate the Ameno menopause program.
- Equity capital raises (private): Recurring venture capital financings including a $44 million Series C (2025) and a $43,999,930 exempt securities offering (Form D, Aug 2025); cumulative funding of $127 million across Series A, B, and C from Insight Partners, Future Ventures, RA Capital, Two Sigma Ventures, Lux Capital, Overwater and others.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | US clinical trial enrollment (no-cost) and ex-US partner-clinic commercial access |
Go-to-market motion4 records
Distribution channels4 records
Marketing channels7 records
Gameto product offering
Product offeringCore offering
Gameto is a clinical-stage biotechnology company that develops cell-engineered therapeutics for the female reproductive system using induced pluripotent stem cell (iPSC) technology. Its lead program, Fertilo, is an investigational OSC-IVM (ovarian support cell in vitro maturation) biologic that co-cultures immature oocytes with iPSC-derived ovarian support cells to mature eggs outside the body in approximately 24 hours, reducing the standard two-week IVF hormone injection protocol to about three days. The company also operates two additional programs: Ameno, a cell therapy targeting menopause symptoms, and Deovo, a drug screening platform for ovarian disease built on Gameto's licensed Harvard meiosis IP.
Product overview
Gameto offers a unified cell engineering platform that powers a portfolio of three named programs targeting women's reproductive health: Fertilo (the lead program, an investigational cell therapy for IVF and egg freezing using iPSC-derived ovarian support cells currently in U.S. Phase 3 trials), Ameno (a cell therapy program for menopause symptoms, including a bioengineered ovarian implant), and Deovo (a drug testing and development platform for ovarian disease). The shared platform—developed with Harvard Medical School and the Wyss Institute—uses transcription factor-directed differentiation of human induced pluripotent stem cells (hiPSCs) into ovarian support cells, and was recently extended with a Harvard meiosis IP license to enable the company's ovary-in-a-dish platform.
Differentiator
Problem solved
Functional benefit
Brands
- Fertilo: Gameto's lead program — an engineered ovarian support cell-based IVF therapy that matures eggs outside the body, making IVF and egg freezing shorter, easier, and more accessible.
- Ameno
- Deovo
Products and services
- Fertilo Gameto's lead investigational cell therapy that uses iPSC-derived engineered ovarian support cells (OSCs) to mature eggs outside the body via OSC-IVM. Designed to make IVF and egg freezing shorter, easier, and more accessible by replacing the conventional ~two-week hormone injection protocol with about three days of minimal stimulation, with engineered cells nurturing eggs for approximately 24 hours before fertilization or freezing. Currently advancing through a U.S. Phase 3 clinical trial at 15 clinics and commercially available in approximately 12 countries outside the U.S.
- Ameno Gameto's cell therapy program for menopause, leveraging proprietary cell engineering to delay the unwanted effects of menopause. Includes development of a steroidogenic hormone-responsive bioengineered ovarian implant with alginate encapsulation of hiPSC-derived ovarian support cells, designed for long-term hormone restoration to address menopause symptoms in the over 1 billion women globally who will experience menopause.
- Deovo Gameto's drug testing and development program for ovarian disease, built on the company's proprietary cell engineering platform. Uses the human ovary-in-a-dish platform (incorporating licensed Harvard meiosis IP) to model human ovarian development and dysfunction for drug screening across multiple ovarian conditions. Aimed at pharmaceutical partners and biotech drug developers targeting ovarian indications.
Quantifiable outcome
- ~80% reduction in hormone medication burden vs. conventional IVF
- +5 more outcomes
Companies that use Gameto
Customer profileSegments4 records
Ideal customer profiles4 records
Gameto technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature7 records
Gameto partnerships and signals
Strategic signalPartnerships
Eleven partnerships are on record, tiered flagship, core and minor.
- Harvard University (Wyss Institute & Professor George Church's lab at Harvard Medical School)flagshipGameto has exclusively licensed intellectual property from Harvard University related to the genetic induction of early meiosis in human cells. The licensed patent portfolio covers genes and methods enabling human oogonia to enter early meiotic stages in vitro and is integrated with Gameto's ovarian organoid platform. The collaboration underpins the company's scientific foundation (CSO Christian Kramme completed his PhD at Harvard Medical School under a Sponsored Research Agreement with Gameto and Professor George Church).
- Prelude Fertility (Martin Varsavsky's network)flagshipChairman Martin Varsavsky is the founder and non-executive chairman of Prelude Fertility, the largest network of fertility clinics in the United States. The Prelude network provides a potential channel and strategic alignment for Gameto's products and was identified as the founder's flagship prior company in the fertility space.
- Boston IVF (Dr. Pietro Bortoletto)coreDr. Pietro Bortoletto serves as a Scientific & Clinical Advisor to Gameto; he is Director of Reproductive Surgery and Co-Director of Oncofertility Program at Boston IVF and Clinical Instructor at Harvard Medical School. Boston IVF is a leading US fertility clinic network.
- CCRM Fertility of New York (Dr. Jaime Knopman)coreDr. Jaime Knopman, Director of Fertility Preservation at CCRM Fertility of New York, serves as a Scientific & Clinical Advisor to Gameto.
- Ruber de Juan Bravo Hospital (Eugin Group; Dr. Daniel Ordóñez Pérez)coreDr. Daniel Ordóñez Pérez, Head of the Assisted Reproduction Unit at Ruber de Juan Bravo Hospital (part of Eugin Group), is a Scientific & Clinical Advisor and has conducted studies of Fertilo with his patients in Madrid, Spain.
- Universitair Ziekenhuis Brussel (Dr. Michel De Vos)coreDr. Michel De Vos, Senior Medical Director at the Centre for Reproductive Medicine at Universitair Ziekenhuis Brussel, Belgium, is a Scientific & Clinical Advisor to Gameto. He is a principal investigator in the FOTO consortium and a leading IVM expert.
- Newcastle University / Newcastle Fertility Centre (Professor Mary Herbert)coreProfessor Mary Herbert, Professor of Reproductive Biology at Newcastle University and Scientific Director at Newcastle Fertility Centre, serves as a Scientific & Clinical Advisor to Gameto.
- Johns Hopkins University (Professor Philip Jordan; Dr. Joshua C. Doloff)minorProfessor Philip Jordan (Biochemistry & Molecular Biology) and Dr. Joshua C. Doloff (Biomedical Engineering) at Johns Hopkins serve as Scientific & Clinical Advisors to Gameto.
- Columbia University (Professor Kristin Baldwin)coreProfessor Kristin Baldwin, Professor of Genetics and Development at Columbia University and member of the Columbia Stem Cell Initiative, serves as a Scientific & Clinical Advisor to Gameto.
- Duke University Medical School (Professor Pranam Chatterjee)coreProfessor Pranam Chatterjee, upcoming Assistant Professor at Duke University Medical School and Research Fellow at Harvard Medical School, serves as a Scientific & Clinical Advisor and is developing state-of-the-art algorithms and high-throughput experimental screens to interrogate germ cell development for Gameto. He holds patents on ScCas9, Sc++, and iSpyMac.
- Accel Recruitment (clinical trial recruitment partner)coreAccel Recruitment hosts Gameto's Phase 3 US clinical trial eligibility screening and enrollment (accelrecruitment.com/ivf-study).
Scale indicators9 records
Recent moves6 records
Expansion highlights6 records
Gameto competitors and assessment
Company assessmentDirect peers
- Overture Life: Co-founded by Gameto Chairman Martin Varsavsky; focuses on automated IVF and embryo engineering. Direct comparable in cell-engineering-based reproductive medicine and shares scientific and investor DNA with Gameto.
- Conceivable Life Sciences: Directly competes with Gameto in engineered egg maturation; co-recognized alongside Gameto at the 2025 World Fertility Awards in the same category. Closest head-to-head peer in iPSC/automation-driven IVF.
Emerging players
- TMRW Life Sciences: Automated, software-tracked cryo-storage for frozen eggs and embryos; serves the same IVF/egg-freezing patient population as Fertilo with an adjacent technology layer rather than a cell-therapy approach.
Broad incumbents
- Ferring Pharmaceuticals: One of the largest incumbents in reproductive medicine (Menopur, Bravelle, Lutrepulse) and a major commercial force in IVF drugs globally. Gameto's commercial advisor Aaron Graff is ex-CEO of Ferring USA, underscoring the direct competitive overlap.
- Merck KGaA (Life Science / Healthcare): Sells Gonal-f (recombinant FSH), one of the gold-standard ovarian stimulation drugs for IVF. Sets the existing standard-of-care protocol that Fertilo's minimal-stimulation approach is designed to disrupt.
- Organon & Co. Spun out of Merck with a focused women's health portfolio including fertility (e.g., Ganirelix, Follistim) and biosimilars. A likely strategic acquirer or competitor for any approved iPSC fertility therapy.
- Vitrolife: Supplies IVF media, culture tools, and time-lapse incubation systems used in conventional IVF labs worldwide. Competes for clinic wallet share and partnership attention even though its offering is consumables rather than cell therapy.
- Progyny: Public fertility benefits manager that sits between employers, clinics, and patients; relevant peer for understanding payer-side adoption dynamics and channel access that any approved Fertilo launch must navigate.
- Kindbody: Operates a national network of fertility clinics and is also a major employer fertility benefits provider; competes with Gameto for clinic channel mindshare and represents a potential commercial partner or acquirer.
Others
- BlueRock Therapeutics: Bayer-owned iPSC-derived cell therapy company (e.g., Parkinson's program); not a reproductive peer but a directly comparable iPSC platform company whose clinical and manufacturing trajectory informs investor expectations for Gameto's platform risk and timeline.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights7 records
Customer concentration
Gameto social profiles
Digital presenceGameto financial estimates
Financial estimateRevenue estimate
Valuation estimate
Gameto leadership team
Management profileNumber of profiles
Profiles12 records
Gameto funding detail
Funding detailFunding overview
Funding rounds6 records
Investors24 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Gameto M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Gameto
What does Gameto do?
Gameto is a clinical-stage biotechnology company that develops cell-engineered therapeutics for the female reproductive system using induced pluripotent stem cell (iPSC) technology. Its lead program, Fertilo, is an investigational OSC-IVM (ovarian support cell in vitro maturation) biologic that co-cultures immature oocytes with iPSC-derived ovarian support cells to mature eggs outside the body in approximately 24 hours, reducing the standard two-week IVF hormone injection protocol to about three days. The company also operates two additional programs: Ameno, a cell therapy targeting menopause symptoms, and Deovo, a drug screening platform for ovarian disease built on Gameto's licensed Harvard meiosis IP.
Is Gameto a public or private company?
Gameto is a private company. It is classified as venture growth investor backed and is currently operating.
When was Gameto founded?
Gameto was founded in 2021. It employs 11 to 50 people.
Where is Gameto based?
Gameto is headquartered in New York, United States, in the North America region.
How does Gameto make money?
Three revenue lines are on record. Pre-commercial / Investigational therapy revenues are the primary driver. The others are non-dilutive grant funding (ARPA-H) and equity capital raises (private).
Who are Gameto's main competitors?
Direct peers on record are Overture Life and Conceivable Life Sciences. TMRW Life Sciences is listed as an emerging player. Broad incumbents are Ferring Pharmaceuticals, Merck KGaA (Life Science / Healthcare), Organon & Co., Vitrolife, Progyny and Kindbody. BlueRock Therapeutics is listed as an others.
Does Gameto have an API?
No public API is recorded for Gameto.
What industry is Gameto in?
Gameto's product category is Cell Therapy. Its primary akta.pro industry code is HLAKAJAC, Reproductive Endocrinology & Infertility (IVF/Fertility), with a secondary code of HLALAHAA, Fertility & Reproductive Endocrinology Telehealth (IVF/IUI, infertility evaluation). Its NAICS code is 325414 and its SIC code is 2834.